{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Defined as being alive and in remission by \\< 5% blasts by bone marrow morphology for patients with myeloid malignancies and CT or PET imaging for patients with lymphoid malignancies at the time of the assessment","groups":[{"description":"Conditioning: Fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1.\n\nCell product: Patients undergo donor peripheral blood stem cell transplant on day 0.\n\nGVHD Prophylaxis: Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"OG000","title":"Treatment (Nonmyeloablative HCT, TBI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years from the date of transplant","title":"Disease-free Survival","type":"SECONDARY","unitOfMeasure":"percent of participants"}